The utility of these biomolecules to treat cancer is due to their ability to bind tumor-associated antigens (e.g., HER2, EGFR, CD20, etc.)overexpressed on the surface of neoplastic cells and their paring with the unique advantages of radionuclides. The gene discussed is EGFR; the disease is cancer.